Search Results for: anticipated spike

Pharmaceutical Temperature-Controlled Packaging Market, 2028 – Pharma TCP Market Digitization to Cut Costs and Streamline Processes – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Temperature-Controlled Packaging for the Pharmaceutical Market” report has been added to ResearchAndMarkets.com’s offering. Pharmaceutical Temperature-Controlled Packaging Market is projected to reach a value of $16.8 billion by 2028 from $10.6 billion in 2023, growing at a CAGR of 9.5%. This research report incorporates an in-depth analysis of the global temperature-controlled packaging market, including … [Read more…]

Oragenics to Participate in the World Vaccine Congress Washington

TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive Officer, will be participating in the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C. Ms. Murphy will be holding meetings to highlight the company’s … [Read more…]

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™

The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is May 2023 NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ (nirmatrelvir … [Read more…]

Rapid Dose Therapeutics Reports Fiscal Year 2022 Financial Results

BURLINGTON, Ontario–(BUSINESS WIRE)–On Friday, January 27, 2023, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), filed its financial results for the fiscal year ended February 28, 2022. Now that the Company has completed the filing of its audited financial statements for the fiscal year ended February 28, 2022 as well as its interim … [Read more…]

$82 Billion Global Vaccines Market 2023 to 2029: Growth Trends, and Market Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vaccines Market – Global Industry Analysis (2019 – 2021), Growth Trends, and Market Forecast (2023 – 2029)” report has been added to ResearchAndMarkets.com’s offering. Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth. This US$90 Bn market (2021) is projected to reach the … [Read more…]

Tevogen Bio CEO Ryan Saadi and CSO Neal Flomenberg share White House concerns about emerging COVID-19 variants and impact on immunocompromised patients, and express commitment to accelerate development of company’s investigational COVID-19 therapy

Tevogen Bio CEO and CSO share concerns of the White House and President Joe Biden who stated, “New variants may make some existing protections ineffective for the immunocompromised” and promise to do everything in their power to accelerate development and manufacturing of its investigational therapy, TVGN-489 A comprehensive review by the company’s R&D team found … [Read more…]

Global Preclinical Medical Device Testing Services Market (2022 to 2030) – Size, Share & Trends Analysis Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Preclinical Medical Device Testing Services Market by Service (Biocompatibility Tests, Chemistry Test, Microbiology & Sterility Testing, Package Validation), by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global preclinical medical device testing services market share is expected to reach USD 4.9 billion by 2030, according to this report. … [Read more…]

Entos Pharmaceuticals Passes Significant Enrollment Milestone in Phase 2 Clinical Trial of its COVID-19 DNA Vaccine

This phase 2 trial evaluates the safety, tolerability, and immunogenicity of Covigenix VAX-001-1b in healthy adults 18 years and older A total of 268 participants have been enrolled in the study at two sites in Burkina Faso, completing the single and two-dose cohorts EDMONTON, Alberta & OUAGADOUGOU, Burkina Faso–(BUSINESS WIRE)–Entos Pharmaceuticals (Entos), a clinical-stage biotechnology … [Read more…]

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of … [Read more…]

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union

CHMP recommendation based on favorable data from Omicron-adapted vaccines The Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine combines 15-ug of mRNA encoding the wild-type spike protein of SARS-CoV-2 in the Original Pfizer-BioNTech COVID-19 Vaccines and 15-ug of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariants Pfizer-BioNTech bivalent Omicron BA.4/BA.5 COVID-19 vaccine is available to … [Read more…]